Study outline
| Group . | MML vaccine (prime) . | MML vaccine (boost) . | MML response . | SIVmac239 infection . | MML vaccine (prime) . | MML vaccine (boost) . | MML response . |
|---|---|---|---|---|---|---|---|
| 1 | Day 0 | Week 4 | Neo | Week 18 | Week 22 | Recall | |
| 2 | Day 0 | Week 4 | Week 8 | Neo | |||
| 3 | Day 0 | Week 4 | Neo | Week 14 | Week 18 | Week 22 | Recall |
| Group . | MML vaccine (prime) . | MML vaccine (boost) . | MML response . | SIVmac239 infection . | MML vaccine (prime) . | MML vaccine (boost) . | MML response . |
|---|---|---|---|---|---|---|---|
| 1 | Day 0 | Week 4 | Neo | Week 18 | Week 22 | Recall | |
| 2 | Day 0 | Week 4 | Week 8 | Neo | |||
| 3 | Day 0 | Week 4 | Neo | Week 14 | Week 18 | Week 22 | Recall |
Each group consisted of 5 RMs. Group 1 was given MML vaccines on day 0 and week 4, and neo MML responses were determined at week 6. MML was again given at weeks 18 and 22, and recall MML responses were determined at week 24. Group 2 was infected with SIVmac239 on day 0, and MML vaccines were given at weeks 4 and 8, and neo MML responses were determined at week 10 in SIV-infected animals. Group 3 was given MML vaccines on day 0 and week 4, and neo MML responses were determined at week 6. Group 3 was then infected with SIVmac239 at week 14, and MML vaccines were again given at weeks 18 and 22, and recall MML responses were determined at week 24 in SIV-infected animals.